Notice: This company has been marked as potentially delisted and may not be actively trading. Neurotrope (NTRP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesShort InterestTrends NTRP vs. AZRX, GHSI, HEPA, YGMZ, ACST, SNSS, BKNG, EXPE, XPO, and MMYTShould you be buying Neurotrope stock or one of its competitors? The main competitors of Neurotrope include AzurRx BioPharma (AZRX), Guardion Health Sciences (GHSI), Hepion Pharmaceuticals (HEPA), MingZhu Logistics (YGMZ), Acasti Pharma (ACST), Sunesis Pharmaceuticals (SNSS), Booking (BKNG), Expedia Group (EXPE), XPO (XPO), and MakeMyTrip (MMYT). Neurotrope vs. AzurRx BioPharma Guardion Health Sciences Hepion Pharmaceuticals MingZhu Logistics Acasti Pharma Sunesis Pharmaceuticals Booking Expedia Group XPO MakeMyTrip AzurRx BioPharma (NASDAQ:AZRX) and Neurotrope (NASDAQ:NTRP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Does the media favor AZRX or NTRP? In the previous week, AzurRx BioPharma's average media sentiment score of 0.00 equaled Neurotrope'saverage media sentiment score. Company Overall Sentiment AzurRx BioPharma Neutral Neurotrope Neutral Which has stronger earnings and valuation, AZRX or NTRP? Neurotrope has higher revenue and earnings than AzurRx BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAzurRx BioPharmaN/AN/A-$32.67M-$11.50-0.03Neurotrope$630K3.54N/AN/AN/A Is AZRX or NTRP more profitable? Neurotrope's return on equity of -286.56% beat AzurRx BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets AzurRx BioPharmaN/A -482.96% -258.47% Neurotrope N/A -286.56%-100.34% Which has more volatility & risk, AZRX or NTRP? AzurRx BioPharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Neurotrope has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Do institutionals and insiders hold more shares of AZRX or NTRP? 6.3% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 3.8% of Neurotrope shares are held by institutional investors. 7.3% of AzurRx BioPharma shares are held by company insiders. Comparatively, 9.7% of Neurotrope shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in AZRX or NTRP? AzurRx BioPharma received 45 more outperform votes than Neurotrope when rated by MarketBeat users. Likewise, 74.26% of users gave AzurRx BioPharma an outperform vote while only 63.38% of users gave Neurotrope an outperform vote. CompanyUnderperformOutperformAzurRx BioPharmaOutperform Votes22574.26% Underperform Votes7825.74% NeurotropeOutperform Votes18063.38% Underperform Votes10436.62% SummaryNeurotrope beats AzurRx BioPharma on 5 of the 8 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Neurotrope News Delivered to You Automatically Sign up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTRP vs. The Competition Export to ExcelMetricNeurotropeTransportation services IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$2.23M$12.37B$8.40B$8.84BDividend YieldN/A7.88%2.77%4.07%P/E RatioN/A12.7215.5514.22Price / Sales3.543.897.8288.42Price / CashN/A27.9233.2236.27Price / Book0.473.893.676.37Net IncomeN/A$368.31M$265.65M$225.56M Neurotrope Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTRPNeurotropeN/A$1.57+1.9%N/AN/A$2.23M$630,000.000.005AZRXAzurRx BioPharmaN/A$0.40-2.4%N/A+50.2%$3.74MN/A-0.0412GHSIGuardion Health SciencesN/A$3.22-2.1%N/A-43.4%$4.35M$12.25M0.6610Gap DownHEPAHepion PharmaceuticalsN/A$0.69-0.6%N/A-78.1%$4.80MN/A0.0020YGMZMingZhu LogisticsN/A$1.14-0.4%N/A-74.6%$5.43M$89M0.00180ACSTAcasti Pharma2.366 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432SNSSSunesis PharmaceuticalsN/AN/AN/AN/A$96.26M$2.07M-2.8124Analyst ForecastGap UpBKNGBooking4.5877 of 5 stars$5,169.18+3.0%$4,785.00-7.4%+58.9%$171.10B$21.37B34.0423,600Analyst ForecastPositive NewsEXPEExpedia Group4.7784 of 5 stars$182.73+2.0%$164.88-9.8%+32.8%$23.45B$12.84B23.0517,100Analyst ForecastInsider TradePositive NewsXPOXPO3.647 of 5 stars$150.87+3.0%$141.13-6.5%+65.9%$17.56B$7.74B47.4238,000MMYTMakeMyTrip2.2015 of 5 stars$109.33+1.9%$98.00-10.4%+149.4%$12.00B$782.52M58.624,576Analyst Downgrade Related Companies and Tools Related Companies AzurRx BioPharma Alternatives Guardion Health Sciences Alternatives Hepion Pharmaceuticals Alternatives MingZhu Logistics Alternatives Acasti Pharma Alternatives Sunesis Pharmaceuticals Alternatives Booking Alternatives Expedia Group Alternatives XPO Alternatives MakeMyTrip Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NTRP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurotrope With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
